Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono spins off biomarker specialist

Led by Jérôme Wojcik, Quartz Bio will operate as a contract research organisation

Merck Serono Geneva HQ

 

Merck Serono has created another spin-off company as part of its entrepreneurship programme, designed to provide start-up opportunities to employees affected by the closure of its Geneva headquarters.

The latest new venture is called Quartz Bio and will operate as a contract research organisation, providing biomarker analysis services to biopharma clients including Merck Serono itself, which has pledged to provide work orders totalling around €2m over the next two to three years.

"Biomarker analysis is a critical step in the drug development process as it enables the identification of patient profiles that are most responsive to a given treatment," said Merck Serono in a statement, with chairman François Naef noting that "highly specialised service companies are essential actors of the drug-development process".

Quartz Bio is the second company to be allocated funding from the start-up fund after Prexton Therapeutics, a Parkinson's disease specialist, was given €2.1m to get off the ground in July.

The €30m entrepreneurship fund is one of a series of measures Merck Serono has set up to help employees who lost their jobs in Switzerland as the company relocated key operations to its German headquarters.

Quartz Bio will be headed by informatics specialist Jérôme Wojcik, along with four other staff, and be located in Plan-les-Ouates in Geneva.

Biomarker-related services are a growth area in the contract research sector and have become increasingly competitive of late, with big CROs such as Quintiles, Covance, WuXi and Parexel all setting up dedicated biomarker business units in the last few years.

Clinical drug development, particularly in the oncology field, is currently the fastest growing sector for biomarker technology and services.

"An increasing number of pharmaceutical companies are integrating a stratified medicine approach in their drug development process in order to predict how patients will respond to a specific therapy," said Wojcik.

"Biomarker analyses are at the heart of stratified medicine," he added.

3rd September 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....